Rhythm Pharmaceuticals (RYTM)
(Delayed Data from NSDQ)
$88.57 USD
-1.67 (-1.85%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $88.56 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Rhythm Pharmaceuticals, Inc. has a market cap of $5.74B, which represents its share price of $90.24 multiplied by its outstanding shares number of 63.62M. As a mid-cap company, RYTM's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
RYTM 88.57 -1.67(-1.85%)
Will RYTM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RYTM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RYTM
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
RYTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates
Other News for RYTM
Rhythm Pharmaceuticals Inc (RYTM) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Rhythm Pharmaceuticals (RYTM) Target Price Increased by Morgan Stanley
Rhythm Pharmaceuticals price target raised by $9 at Morgan Stanley, here's why
Q2 2025 Rhythm Pharmaceuticals Inc Earnings Call Transcript
Rhythm (RYTM) Forecasts 2025 Non-GAAP Operating Expenses